Publication | Closed Access

The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats

Cannabis UseZucker RatsPsychoactive DrugHealth SciencesFunctional SelectivityMedicineMetabolic BenefitsPhysiologyLong-term TreatmentExperimental PharmacologyPharmacotherapyMetabolomicsPharmacologyCannabinoid PharmacologyCannabinoidsDrug DiscoveryCannabis